LifeLabs Medical Laboratory Services

LifeLabs Medical Laboratory Services

March 19, 2015 14:00 ET

LifeLabs Medical Laboratory Services Offers Prosigna™ Breast Cancer Prognostic Genetic Test Across Canada

TORONTO, ONTARIO and VANCOUVER, BRITISH COLUMBIA--(Marketwired - March 19, 2015) -

Attention Business & Healthcare Editors

LifeLabs Medical Laboratory Services ("LifeLabs") today announced the commercial availability of the Prosigna™ Breast Cancer Prognostic Gene Signature Assay ("Prosigna") in Canada. Prosigna is a molecular test that assesses the genetic profile of cells found in breast cancer tissue. This information is used to assess the future (10 year) risk of recurrence of cancer in postmenopausal, hormone-receptor positive women with early stage breast cancer. Prosigna is the first and only diagnostic molecular test in its class to be approved by Health Canada, enabling Canadian oncologists and pathologists to meet the diagnostic and treatment needs of breast cancer patients without sending tissue samples outside of Canada.

"LifeLabs is pleased to be the first clinical lab in Canada to offer the Prosigna test," said Sue Paish, CEO of LifeLabs, Canada's largest community based laboratory services company. "This test can help physicians determine whether breast cancer patients will benefit from chemotherapy treatment or whether other treatment options are more appropriate. By providing this molecular test in Canada, physicians can make quicker treatment decisions by having faster access to important clinical information."

Breast cancer is the most common cancer in women worldwide, with an estimated 24,400 Canadian women diagnosed in 2014 (Canadian Cancer Society, 2015). For those with early breast cancer, chemotherapy is often given after surgery, but before radiation therapy, to help lower the risk of recurrence by ridding the body of cancer cells that might still be present. While chemotherapy and radiation have had a substantial impact on outcomes, a sizeable number of postmenopausal women with certain types of breast cancer remain at risk for late recurrences. The Prosigna test helps physicians assess a patient's likelihood of recurrence at 10 years and may help enhance treatment decisions.

"LifeLabs is committed to building a healthier Canada through the delivery of exceptional diagnostic testing, innovation, analysis, information and service," said Sue Paish. "Genetic testing is a significant element of the future of health care and LifeLabs is delivering leading edge tests that will allow treatments tailored to each individual's unique genetic blueprint - truly personalizing medicine."

This announcement is another example of LifeLabs' commitment to the development of genetic expertise and to the deployment of effective genetic testing across Canada. In addition to the Prosigna Assay, LifeLabs has established partnerships with Centogene, Contextual Genomics and Natera. Genetic and genomic testing are the fastest growing segments in laboratory medicine and have the potential to offer a new standard of care and provide better clinical outcomes for Canadian patients.

More information about Prosigna can be found by visiting the LifeLabs Genetics website or by emailing Ask.Genetics@LifeLabs.com.

About LifeLabs: www.LifeLabs.com

LifeLabs is a Canadian-owned company and is the country's largest provider of community laboratory services with over 50 years of experience providing laboratory testing services to help health care providers diagnose, treat, monitor and prevent disease in patients. In communities across British Columbia and Ontario, LifeLabs delivers cost-effective, convenient access to laboratory testing services which are essential for optimal outcomes in health care. LifeLabs employs approximately 5,400 professionally trained staff and delivers over 100 million laboratory tests, serving 19 million patients annually. In 2013, LifeLabs acquired BC Biomedical in British Columbia and CML HealthCare in Ontario making LifeLabs the largest community laboratory in Canada. LifeLabs is indirectly owned by OMERS Administration Corporation, whose interest is managed by Borealis Infrastructure. For more information about LifeLabs Genetics, visit www.LifeLabsGenetics.com. LifeLabs is a Proud Supporter of the TORONTO 2015 Pan Am/Parapan Am Games.

About Borealis Infrastructure Management Inc. www.borealis.ca.

Borealis is a leader in direct infrastructure investing with over a decade of investment experience. Borealis manages approximately CAD 10 billion in OMERS equity capital through investments in a diversified portfolio of large-scale infrastructure assets exhibiting stability and strong cash flows, in sectors including energy, transportation and government regulated services. It has offices in Toronto, London and New York. Borealis is the infrastructure investment arm of OMERS, one of Canada's largest pension funds with over CAD 72 billion in net assets.

Contact Information